What's at stake: Aroa has been long on promise and short on delivery. This result suggests that may be changing for the better.
Background: Aroa listed on the ASX in 2020 with the shares at A75 cents. They surged to A$1.40 on debut but have never surpassed that. Even with today's jump, the shares are at A54 cents.
Main players: Brian Ward, Aroa founder and CEO. Retail investors who hold 46% of the company.
Shares in New Zealand-based and ASX-listed medical technology company Aroa Biosurgery spiked by almost 15% in morning trade today after the company rewarded the patience of investors with a full year profit.
Aroa’s announced full year ebitda of $4.2m for the year to the end of March, ahead of the
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: Aroa has been long on promise and short on delivery. This result suggests that may be changing for the better.
Background: Aroa listed on the ASX in 2020 with the shares at A75 cents. They surged to A$1.40 on debut but have never surpassed that. Even with today's jump, the shares are at A54 cents.
Main players: Brian Ward, Aroa founder and CEO. Retail investors who hold 46% of the company.
